Modulation of tissue factor and tissue factor pathway inhibitor-1 by neutrophil proteases

Birgit A. Steppich; Isabell Seitz; Gabi Busch; Andreas Stein; Ilka Ott

doi:10.1160/TH08-05-0293

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(06): 1068-1075
DOI: 10.1160/TH08-05-0293

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Modulation of tissue factor and tissue factor pathway inhibitor-1 by neutrophil proteases

Birgit A. Steppich

¹Deutsches Herzzentrum der Technischen Universität München, Munich, Germany

,

Isabell Seitz

¹Deutsches Herzzentrum der Technischen Universität München, Munich, Germany

,

Gabi Busch

¹Deutsches Herzzentrum der Technischen Universität München, Munich, Germany

,

Andreas Stein

¹Deutsches Herzzentrum der Technischen Universität München, Munich, Germany

,

Ilka Ott

¹Deutsches Herzzentrum der Technischen Universität München, Munich, Germany

› Author Affiliations

Abstract

Summary

During systemic inflammation, neutrophil activation is accompanied by endothelial cell damage and hypercoagulability. Activated neutrophils release serine proteases that participate in tissue injury.We sought to investigate the effects of neutrophil proteases on proinflammatory and procoagulant changes in endothelial cells.The effects of elastase (HNE), cathepsin G (CG), and proteinase 3 (PR3) on expression of tissue factor (TF) and tissue factor pathway inhibitor-1 (TFPI) were examined in human umbilical vein endothelial cells. Flow cytometry demonstrated that these proteases proteolytically degraded endothelial cell-bound TFPI. TFPI mRNA expression was reduced by HNE and CG. PR3, but not HNE or CG, increased surface expression of TF and TF mRNA.Yet, increased TF expression did not enhance TF activity suggesting induction of encrypted TF. Using antibodies and siRNA to inhibit and silence PAR-1 and PAR-2, we observed that PR3 upregulation of TF is at least in part mediated by PAR-1.Although CG and HNE cleaved PAR-1, antibody reactivity to the PAR-1 hirudin-like sequence demonstrated inactivating cleavage, accounting for the selective ability of PR3 to induce PAR-1-mediated procoagulant effects.This was supported by induction of p42/44 MAPK by PR3. In conclusion, PR3 degradation of TFPI increases the procoagulant activity of endothelial cells. Release of PR3 after neutrophil activation may represent an important step in neutrophil-mediated vascular injury.

Keywords

Tissue factor (TF) - tissue factor pathway inhibitor (TFPI) - proteinase 3 - cathepsin G - human neutrophil elastase

Full Text

References

References
1 Brown KA, Brain SD, Pearson JD. et al. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368: 157-169.
2 Singer M, De Santis V, Vitale D. et al. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004; 364: 545-548.
3 Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005; 128: 2864-2875.
4 Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101: 3765-3777.
5 Ott I, Malcouvier V, Schomig A. et al. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation 2002; 105: 279-281.
6 Steppich B, Mattisek C, Sobczyk D. et al. Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. Thromb Haemost 2005; 93: 35-39.
7 Higuchi DA, Wun TC, Likert KM. et al. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79: 1712-1719.
8 Petersen LC, Bjorn SE, Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992; 67: 537-541.
9 Gando S, Kameue T, Matsuda N. et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor inARDS patients. Thromb Res 2003; 109: 119-124.
10 Gando S, Kameue T, Morimoto Y. et al. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002; 30: 1729-1734.
11 Seitz I, Hess S, Schulz H. et al. Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 769-775.
12 Ott I, Vukovich R, Schomig A. et al. Overexpression of glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor-1 inhibits tissue factor activity. Blood Coagul Fibrinolysis 2003; 14: 539-544.
13 Ott I, Andrassy M, Zieglgansberger D. et al. Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1. Blood 2001; 97: 3721-3726.
14 Ott I, Miyagi Y, Miyazaki K. et al. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000; 20: 874-882.
15 Broze Jr GJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995; 06 (Suppl. 01) S7-13.
16 Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 2006; 06: 541-550.
17 Ottonello L, Barbera P, Dapino P. et al. Chemoattractant-induced release of elastase by lipopolysaccharide (LPS)-primed neutrophils; inhibitory effect of the anti-inflammatory drug nimesulide. Clin Exp Immunol 1997; 110: 139-143.
18 Bogdanov VY, Balasubramanian V, Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 09: 458-462.
19 Ahamed J, Versteeg HH, Kerver M. et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 2006; 103: 13932-13937.
20 Caplice NM, Mueske CS, Kleppe LS. et al. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998; 98: 1051-1057.
21 Saigo M, Abe S, Ogawa M. et al. Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost 2001; 86: 1197-1203.
22 Toschi V, Gallo R, Lettino M. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
23 Wilcox JN, Smith KM, Schwartz SM. et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
24 Eling M, Stephens AC, Oragui EE. et al. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease. Thromb Haemost 2001; 85: 240-244.
25 Shimura M, Wada H, Wakita Y. et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1997; 55: 169-174.
26 Skold S, Rosberg B, Olofsson T. The N-terminal tetrapeptide of neutrophil proteinase 3 causes S-phase arrest in granulopoietic progenitors. Exp Hematol 2005; 33: 1329-1336.
27 Kurosawa S, Esmon CT, Stearns-Kurosawa DJ. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol 2000; 165: 4697-4703.
28 Taekema-Roelvink ME, Van Kooten C, Heemskerk E. et al. Proteinase3 interacts with a 111-kD membrane molecule of human umbilical vein endothelial cells. J Am Soc Nephrol 2000; 11: 640-648.